A new drug application was submitted to the FDA for oral formula to treat smallpox.
MicroRNAs are currently under investigation for various clinical applications in infectious disease because of their role in host response to infection and effects on innate and adaptive immune pathways.
A study investigated whether fecal microbiota transplantation delivered via oral capsules was as effective as microbiota delivered via colonoscopy for treating recurrent Clostridium difficile infection.
The highest SVR12 rates were obtained with 12 weeks of LDV/SOF+RBV in noncirrhotic participants and by extending the duration of LDV/SOF treatment to 24 weeks in cirrhotic individuals.
The FDA has granted Fast Track designation to Visterra's lead product, VIS410.
Trimethoprim-sulfamethoxazole appears to improve cure rates after incision and drainage of MRSA abscesses regardless of patient characteristics.
A representative from the California Department of Public Health discusses latent TB infection testing and treatment recommendations and reasons why US physicians have been slow to test for and treat for the condition.
Updated labeling has been provided for several treatments for hepatitis C virus infections.
The results of this study question the routine empirical use of macrolide combination therapy in this population.
Mortality rates associated with infective endocarditis range from 16% to 25%, with the highest rates observed among patients with nosocomial healthcare-associated infective endocarditis.
The iAdhere study found that once-weekly self-administration of isoniazid and rifapentine had high treatment completion rates in the United States, Hong Kong, Spain, and South Africa.
Further research on longer-term effects of maternal prenatal TDF use is important given the majority of HIV-infected women are prescribed a TDF-containing prevention of mother-to-child transmission regimen.
Switching to dolutegravir plus darunavir/ritonavir provided a simple and safe rescue regimen, controlling viral replication in a high proportion of patients.
NSAIDs were found to be inferior to antibiotics for symptom relief of uncomplicated urinary tract infection.
Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, exhibit potent antiviral activity across all six major HCV genotypes.
Zanamivir is a neuraminidase inhibitor approved in the United States as an oral inhalation powder for acute, uncomplicated influenza in children ≥7 years of age and prophylaxis in children ≥5 years of age.
Researchers examine serious infection risk factors in patients with juvenile idiopathic arthritis receiving biologic therapy.
The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved treatment adherence, and a reduced rate of side effects.
Refractory Helicobacter pylori infection can be successfully treated with goshuyuto and rabeprazole.
Vabomere is now available for the treatment of adults (≥18 years old) with complicated urinary tract infections.
Treatment of hepatitis C virus with direct-acting antivirals was tied to a 71% reduction in the risk of liver cancer.
Secnidazole is a 5-nitroimidazole with demonstrated in vitro antimicrobial activity against many anaerobic Gram-negative and Gram-positive bacterial species, while sparing Lactobacillus species.
For uncomplicated Gram-negative bloodstream infections, oral beta-lactam therapy may be an appropriate stepdown option.
Researchers conducted a systemic review and meta-analysis to determine which antibiotics for systemic use were associated with the lowest risk of C difficile infection.
Inappropriate prescribing of outpatient antibiotics for the treatment of uncomplicated urinary tract infections are higher than previously estimated.
Patients who seem to benefit most from the combination of a macrolide with a β-lactam are patients with bacteremic pneumococcal pneumonia, septic shock, and invasive mechanical ventilation.
Only a small percentage of people with HIV/HCV co-infection receive treatment for hepatitis C.
Hear from experts on when to prescribe short course antibiotic therapy in pediatric populations for a variety of common infections.
Weight-based dosing options for treatment may improve clinical outcomes in patients with cellulitis.
Three months of rifapentine + isoniazid using directly observed therapy resulted in a higher completion rate and no loss of follow-up for latent tuberculosis.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Climate Change: Effects on the Incidence and Distribution of Infectious Diseases
- Improving Campaigns Regarding the Value of Adult Vaccines
- Seminal HPV Infection Prevalent Worldwide, May Affect Male Fertility
- Pausing ART to Identify Biomarkers for HIV RNA Rebound: Safety and Ethical Considerations
- MicroRNAs in Infectious Disease: Emerging Clinical Applications
- Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults
- SVR Achieved With Sofosbuvir, Grazoprevir/Elbasvir Plus Ribavirin in HCV
- First Oral Smallpox Treatment Submitted to FDA for NDA
- Trends in Meningococcal Disease Following MenACWY Vaccine Introduction
- Clinician Accuracy Evaluated for Lyme Disease